Invention Grant
- Patent Title: Chemically modified messenger RNA's
-
Application No.: US16083327Application Date: 2017-03-08
-
Publication No.: US11377656B2Publication Date: 2022-07-05
- Inventor: Shari Lynn Caplan , Katsumasa Nakajima
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Linyu L. Mitra
- International Application: PCT/IB2017/051367 WO 20170308
- International Announcement: WO2017/153936 WO 20170914
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12N15/11 ; C07H21/02 ; C12N15/87

Abstract:
This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.
Public/Granted literature
- US20190100752A1 CHEMICALLY MODIFIED MESSENGER RNA'S Public/Granted day:2019-04-04
Information query